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Summary.-Tumour metastasis in BCG-pretreated mice was studied using a
methylcholanthrene-induced fibrosarcoma in C3H/He mice. When tumour cells were
injected into the BCG-primed site, distant metastasis occurred in the lungs and the
popliteal lymph node, though this tumour did not metastasize in normal mice. Such
metastases were increased in proportion to the number of tumour cells injected into
the BCG-primed site, and developed soon after tumour challenge. Concomitant
immunity developed well in the mice bearing such metastases, but did not inhibit
metastatic growth. Experiments using 1251-labelled SRBC or tumour cells revealed
that such cells egressed rapidly from the BCG-primed site. When the tumour was
inoculated into the contralateral foot to the BCG-primed site, the incidence and the
number of metastases was reduced. Furthermore, BCG infection induced an increase
of platelet count. I.v. injection of this tumour induced marked thrombocytopenia in
normal mice. Administration of pentoxifylline, a methylxanthine derivative, before
tumour challenge reduced such metastases. These findings suggest that the changes
in peripheral blood, such as increased platelet count and increased release of tumour
cells from the injection site, facilitated distant metastasis in BCG-pretreated mice.
WE HAVE PREVIOUSLY REPORTED that a
high dose of MCA-induced fibrosarcoma
injected at a BCG-primed site induced
distant metastases in the draining lymph
node and the lungs, whereas this same
tumour did not metastasize in normal mice
(Ishibashi et al., 1978a). The mechanisms
responsible for this tumour spread in
BCG-primed mice are not known. How-
ever it was also found previously that the
direct plaque-forming cells (PFC) were
produced in various widely distributed
lymphoid organs such as spleen and axil-
lary lymph node, when sheep red blood
cells were injected into the BCG-primed
footpad, whereas in normal mice the direct
PFC were mainly found in the draining
popliteal lymph node after SRBC injec-
tion into the hind foot pad. (Ishibashi
et al., 1978b). These findings suggestedthat
the inflammatory changes produced by
BCG infection would facilitate the migra-
tion offoreign bodies such as SRBC to the
distant organs. The purpose ofthe present
paper is to report the facilitation of migra-
tion oftumour cells injected into the BCG-
primed site and the development of meta-
stasis, and to analyse the mechanisms of
the promotion of such metastasis.
MATERIALS AND METHODS
Animals.-Male and female C3H/He mice
were used throughout the experiments. They
were obtained from the animal supply centre
in Kyushu University. Animals were 8 weeks
old at the beginning of the experiments. In
each experiment, mice of same age and sex
were divided into 2 groups. One group of
mice was injected with BCG and the other
group without BCG injection served as con-
temporaneous controls.
BCG.-Lyophilized BCG, Strain Japan,
was obtained from theJapan BCG LaboratoryT. ISHIBASHI El' AL.
(Tokyo, Japan). One mg ofBCG was injected
into the hind foot pad in a volume of0 05 ml
ofsaline.
Tumour and tumour transplantation.-A
previously described MCA-induced fibro-
sarcoma was used throughout the experi-
ments. The tumour-cell suspension was
prepared according to the method described
previously (Ishibashi et al., 1978a). Mice were
injected in the hind foot pad with 0 05 ml of
tumour suspension or s.c. in the centre ofthe
back in a volume of 041 ml. Tumour growth
in the back was expressed as the mean of
perpendicular diameters. Tumour immunity
was tested by the classical test of tumour
inoculation, excision and subsequent chal-
lenge with tumour. Metastases in the pop-
liteal lymph node and lungs were examined
macroscopically and histologically. Pul-
monary metastases were counted under a
dissectingmicroscope. When 2-5 x 105 tumour
cells were injected into the BCG-primed foot
pad, the number of resultant pulmonary
metastases was usually less than 20.
Iodination of SRBC and tumour cells..
Enzymatic radioiodination was carried out
according to the method described by Schen-
kein et al. (1972). One ml of the incubation
mixture contained 109 SRBC or 106 tumour
cells in phosphate-buffered saline, 15 ,tg of
glucose oxidase (Sigma Chemical Co., St
Louis, Mo., Type VII) 5 mg ofglucose, 0-1 mg
of lactoperoxidase (P-L Biochemicals, Inc.,
Milwaukee, Wis.) and 0-2 mCi of carrier-free
Na 125J (New England Nuclear Corp., Boston,
Mass.). Incubation was carried out for 20
min at 37°C with constant agitation. There-
after the cells were rinsed 7 x in cold phos-
phate-buffered saline. Schenkein et al. (1972)
noted that this method produced a marked
increase in the incorporation of radioactivity
in the cell surface, and a significant improve-
ment ofcell survival.
Distribution of 125I-labelled SRBC or tumour
cells injected into the BCG-primed site.-
3 x 107 labelled SRBC or 2-5 x 105 labelled
tumour cells were injected into the BCG-
primed foot pad. Animals were killed at
varying times after such injection. Radio-
activity in the foot pad injected with labelled
cells, popliteal, inguinal and axillary lymph
node, spleen and lungs was measured with a
Nuclear Chicago auto-well scintillation coun-
ter. Results were expressed as a percentage of
aliquots of labelled cells taken at the time of
injection.
Statistical method.-The data were analysed
by Student's t test.
RESULTS
Confirmation of distant metastasis induced
by BCG
Mice were inoculated with 1 mg of
BCG into the right hind foot pad 7 weeks
before tumour challenge. Various doses of
tumour cells were injected into the BCG-
primed site. Mice were necropsied 4 weeks
after tumour challenge. The results in
Table I showed that the incidence of
TABLE I.-Metastasis in mice inoculated
with tumour at the BCG-primed site*
No. of
tumouIr
cells
inoculated
in 0 05 ml
2 x 105
5 x 104
2 x 104
No. of
mice with
primary
tumour
8/10
4/8
4/10
No. ofmice with
metastases 4 weeks
after tumour
challenge
Popliteal
lymph
node Lung
7/10 6/10
2/8 not tested
1/10 1/10
* 1 mg of BCG injected into the right hindl foot
pad 7 weeks before tumour challenge.
primary tumour grew and distant meta-
stasis was increased in proportion to the
number of tumour cells injected.
Early occurrence ofdistant metastasis
The experiment was performed to
determine whether distant metastasis
occurred soon after tumour challenge.
Mice were divided into 5 groips. One
group of mice served as normal controls
without BCG pretreatment. The other 4
groups of mice were inoculated with 1 mg
of BCG into the right hind foot pad 7
weeks before tumour challenge. Mice ofall
groups were injected with 2 x 105 tumour
cells into the right hind foot pad (BCG-
primed site). The tumour-injected foot
pads of 3 groups pretreated with BCG were
amputated above the ankle joint respec-
tively 1, 3 and 7 days after tumour chal-
lenge. Five weeks later, the mice were
killed and metastases examined. As shown
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TABLE II.-Metastasis in
with tumour at the B(
followed by tumour excisi
I
m
Po
13
r Group Treatment*
1
2
3
4
5
BCG
BCG, tumour excision
1 day later
BCG, tumour excision
3 days later
BCG, tumour excision
7 days later
* All mice were injected with 2
in the right hind foot pad (BCG-1
in Table II, distant metasl
even in the mice undergo
the tumour-site one day aft
lenge, indicating that the e
cellsfromthe injection site
diately after tumour ino(
BCG-primed site.
Organ distribution of 125]
injected into the BCG-primr
Histological examinatio
8-week-old BCG granulomC
of clusters of macropha
"foamy" cells. Lymphocy
spersed around the macr(
and capillary formation
around their outer layer.
suggested that foreign bodi
such granuloma would easi
mice inoculated the injection site. In the next experiment
7/C-primed site, mice were inoculated with 1 mg of BCG
yon into the right hind foot pad. Normal mice
No. ofmice witti without BCG injection served as con-
etastases 5 weeks temporaneous controls. All mice were
aftertumour injected with 3 x 107 1251-labelled SRBC
g A into the right hind foot pad 8 weeks after
pliteal BCG. Radioactivity in various organs was
odpeh Lung measured 3, 24 and 72 h after SRBC
0/5 o0s injection. As shown in Table III, labelled
4/5 4/5 SRBC migrated out immediately after
2/7 4/7 injection, whether normal or BCG pre-
treated. The foot pad retained only 5.3%
2/6 3/6 of the injected dose in normal mice, and
5/7 3/7 3.8% in BCG-pretreated mice at 72 h.
2x i0 tumour cells But the decrease ofradioactivity in BCG-
primed site). primed foot pad was significantly more
rapid than that seen in normal foot pad
tases developed at the times examined. On the other hand
ing excision of the uptake of labelled SRBC in the drain-
tertumour chal- ing popliteal node ofBCG-pretreated mice
gress oftumour increased significantly faster than that
occurredimme- seen in controls at any time. Moreover
culation at the the peak uptake of labelled SRBC in the
popliteal node was seen at 3 h in BCG-
r'-labelle SRBC pretreated mice, whereas it reached a
-labelled SRBO peak at 24 h in controls. The uptake of
ed site labelled SRBC in distant organs such as
in showed that inguinal lymph node, spleen and lungs, in
a was composed BCG-pretreated mice was higher than that
ges resembling in controls at 3 h, although the differences
*tes were inter- between both groups were not significant.
ophage clusters
was increased Organ distribution of 125klabelled tumour
These findings cells injected into the BCG-primed site
ies injected into Mice were injected with 2-5 x 105 1251-
.ly migrate from labelled tumour cells into the right hind
TABLE III.-Organ distribution* of 125I-labelled SRBBt injected at the BCG-primed site
Time after injection
1- A E
3 h
, 1 A~~
24 h
( K ~~~
Organ Control BCG Control BCG Contr
Foot pad 41-6 + 6-2 32-4 +4-7t 15-2 + 0-6 11-3+2-6§ 5-3 +
Popliteal node 0-18+ 0-05 0 86 + 02411 0-24 + 0-02 084+0 2111 0-18+0
Inguinal node 0 05 + 0-02 0 34 + 0-38 0 03 + 0-005 0 03 + 0 009 0 03 + 0
Spleen 0-19 + 0 04 0-24+ 0 05 0 05+ 0 003 0-06 + 0-006 0 04+ a
Lung 0-28 + 0-17 0-42 + 0-29 0-06 + 0-007 0-06 + 0-008 0 04+ a
* % of injected counts+ s.d.
t 3 x 107 125I-labelled SRBC (390,000 ct/min) injected into the right hind foot pad.
t 0-02 <P < 0 05 in comparison with control.
§ P < 0-02 in comparison with control.
11 P < 0-001 in comparison with control.
72 h
rol BCG
0)3 38+0411
)I05 043+0-1411
D-005 0 03 + 0-001
D-003 0 05+ 0-006
D-002 0 05+ 0 003
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TABLE IV.-Organ distribution of 1251-labelled tumour cells* injected at the BCG-primed
site
Time after injection
A
BCG
25-7 +3-2T
1-56+ 0-55t
0-30+ 0-12
0-27 + 0-05
0-38+ 0-13
24 h
,T (
Control BCG
13-8 + 1-6
033 + 0-06
0-08 + 0-02
0-16 + 0-02
0-23 + 0-02
15-0 + 2-2
0-71 + 0-32§
0-16 + 0-14
0-20 + 0-06
0-29 + 0-16
72 h
r-
Control BCG
7-9 +0 7 7-4 +0-8
0-17+0-04 0-43+0-16$
0-07+0-00 0-10+0-05
0-08 + 0 00 0-08 + 0-01
0-11+ 0-01 0-11 + 0-01
* 2-5 x 105 1251-labelled tumour cells (166,000 ct/min) injected into the right hind foot pad.
t P < 0-01 in comparison with control.
t P < 0-02 in comparison with control.
§ P < 0-05 in comparison with control.
foot pad with or without BCG pretreat-
ment. Mice were killed after 3, 24 and 72 h
and radioactivity in various organs was
measured. As shown in Table IV, the
change in the pattern of distribution of
tumour cells was essentially the same as
that seen after SRBC injection. The peak
uptake of labelled tumour cells in the
lungs was 0.36% of the injected dose in
controls, 0.38% in BCG-pretreated mice.
Metastasis in mice inoculated with tumour
cells at a site distant from the BCG-primed
site
Firstly, the development of metastasis
was examined in the case oftumour inocu-
lation at the contralateral foot pad to the
BCG-primed site. Mice were divided into
TABLE V. Metastasis in mice inoculated
with tumour at a site distant from the
BCG-primed site
BCG
treat-
Group ment
1 +
2 +
3
Site of
tumour
inoculation*
BCG-primed
foot pad
Contralateral
foot pad
Foot pad
No. of mice
with
metastases
24 days after
tumour
challenge
Pop-
liteal
lymph
node Lung
2/7 5/7 '
0/7 2/7 1
No. of
pul-
monary
tumours
2, 3, 4,
14, 22
1, 1
0/7 0/7
* 2 x 105 tumour cells inoculated into the foot pad
indicated.
3 groups. Groups 1 and 2 were injected
with 1 mg of BCG into the right hind foot
pad. Group 3 mice without pretreatment
served as normal controls. Seven weeks
later 2 x 105 tumour cells were injected
into the BCG-primed foot pad in Group 1,
into the contralateral foot pad in Group 2
and into the right hind foot pad in Group
3. The results are presented in Table V.
Even in the mice inoculated with tumour
into the contralateral foot pad, pulmonary
metastasis was evident, but its incidence
and the number of metastatic tumours in
thelung wasdistinctly lessthaninthe mice
inoculated with tumour at the BCG-
primed site. In the next experiment, pul-
monary metastasis after i.v. injection of
tumour cells was examined in BCG-
pretreated mice. Normal and BCG-pre-
treated mice were each divided into 2
groups. Each paired group of normal and
BCG-pretreated mice was injected i.v.
either with 5 x 104 or 2 x 105 tumour cells.
TABLE VI.-Pulmonary metastasis pro-
duced by i.v. inoculation oftumour cells in
BCOG-pretreated mice
No. of
tumour
cells
No. BCG inoculated
of treat- (in 0-2 ml
Group mice ment i.v.)
1
2
3
4
6
7
6
7
+ 5x 104
5 x 104
2 x 105
2 x 105
Average number
ofpulmonary
tumours (and
range) 24 days
after tumour
challenge
3-7+1-4 (2-5)*
15-9+6-8 (8-26)
54-8 + 15-3 (32-74)
41-8 + 18-2 (20-74)
* P < 0-01 in comparison with Group 2.
C--
3 h
Organ
Foot pad
Popliteal node
Inguinal node
Spleen
Lung
Control
33-3 + 4-2 2
0-28 + 0 07
0.11 + 0-03
0-21 + 0 05
0-36 + 0 07
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Mice were killed 24 days after tumour
challenge and the pulmonary metastases
counted. The results are summarized in
Table VI. When a low dose of tumour
inoculum, such as 5 x 104 tumour cells,
was injected, BCG pretreatment clearly
reduced the resultant number of pul-
monary metastases. On the other hand,
BCG pretreatment increased rather than
reduced the number of pulmonary meta-
stases after a high tumour dose inocula-
tion.
Tumour immunity in mice pretreated with
BCOG
Mice were divided into 3 groups. Group
1 mice were injected with 1 mg ofBCGinto
the right hind foot pad. Group 2 and 3
mice received no BCG. Seven weeks after
BCG injection, Groups 1 and 2 were
injected with 5 x 104 tumour cells into the
right hind foot pad and 2 weeks later the
_10 jt
E I
N
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0
E
I-1
-22 -7 0 4 7 9 11 14
t 1 t
Tumour Amputation DAYS
cells Tumour
5x104 challenge
2x105
FIG.-Tumour growth in mice pretreated
witlh BCG, tumour cells and subsequent
excision:
Group 1 mice (A) were injected with 1
mg of BCG into the right hind foot pad.
7 weeks later, mice of Group 1 and 2 (0)
were injected with 5 x 104 tumour cells into
the right hind foot pad and 2 weeks later
the tumour sites were excised. Group 3
mice (0) served as normal controls. All
mice were challenged with 2 x 105 tumour
cells into the back one week after tumour
excision. No. of mice with tumour de-
veloped/total mice in each group was:
Group 1, 3/6; Group 2, 6/7; Group 3, 6/6.
tumour site of both groups were ampu-
tated. Group 3 mice without treatment
served as normal controls. All mice were
concurrently injected with 2 x 105 tumour
cells into the centre of the back one week
after tumour excision. The results in the
Figure show that tumour growth was
strongly suppressed in both immunized
groups as compared to controls. The
differences between both immunized
groups and control group were significant
to P <0(001 at the times examined. The
suppression of tumour growth in mice
immunized with tumour at the BCG-
primed site was greater than that in the
mice immunized with tumour only, but the
difference was not significant.
The next experiment was performed to
determine whether the primary growing
tumour affected the immunity to rechal-
lenged tumour. Mice were divided into 5
groups. Groups 1 and 2 were inoculated
with 1 mg ofBCG into the right hind foot
pad. Group 3 and 4 served as tumour
control without BCG pretreatment. Seven
weeks after BCG injection, mice ofGroups
1 to 4 were injected with 105 tumour
cells, as a high tumour dose, into the right
hind foot pad (BCG-primed site). Group 5
received no pretreatment as normal con-
trols. Two weeks after tumour inoculation.
the primary tumour of Groups 2 and 4
was excised. All mice were rechallenged
with 2 x 105 tumour cells in the back one
week after excision ofthe primary tumour.
Mice were killed 2 weeks after tumour
rechallenge and the metastases examined.
The results are summarized in Table VII.
Rejection and growth of rechallenging
tumours of the mice bearing primary
tumour at the BCG-primed site (Group 1)
was similar to that in the mice undergoing
excision of primary tumour at the BCG
site (Group 2). However, immunity to
rechallenging tumour in the mice bearing
primary growing tumour without BCG
pretreatment (Group 3) was slightly lower
than in mice undergoing excision of pri-
mary tumour (Group 4). In contrast,
distant metastases in the draining node
and lungs were observed only in mice
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TABLE VII.-Tumour immunity and metastasis in mice inoculated with tumnour* at the
BCO site, followed by tumour excision 2 weeks later
No. of
mice with
rechallenged No. of mice with
tumour Sizet of each metastasest
growing/ rechallenged , A
Total No. tumour Lymph
Group Treatment of mice (mm) node Lungs
1 BCG, tumour 1/4 2 2/4 2/4
2
3
4
5
BCG, tumour,
excision
Tumour
Tumour, excision
0/5
2/5
0/4
5/5
2, 9
9, 8, 12, 8, 10
2/5
0/5
0/4
0/5
3/5
0/5
0/4
0/5
* 105 cells in the right hind foot pad. All mice were rechallenged with 2 x 105 tumour cells in the back
one week after excision of primary tumour.
t Measured at the tine ofkilling and expressed as the mean ofperpendicular diameters.
t Killed 2 weeks after tumour rechallenge.
pretreated with BCG. The occurrence of
distant metastases was similar between
both groups of the BCG-pretreated mice,
with or without tumour excision.
Peripheral-blood changes in BCG infected
mice
Mice were inoculated with 1 mg ofBCG
into one hind foot pad. Haematological
examination of blood obtained from the
tail vein was made 4, 8 and 12 weeks after
BCG infection. Red blood cells, white
blood cells and platelets were counted
with a haemacytometer. The results are
presented in Table VIII. The RBC count
and the platelet count increased after
BCG infection. The significance of the
differences between the RBC count of
normal control mice and those of BCG
infected mice was P< 0 001 and P< 0 01
respectively, 4 and 8 weeks after BCG
infection. The platelet count showed a
significant increase 12 weeks after BCG
infection (P<0.05). There are no signi-
ficantchanges intheWBC count.Although
the data were not shown, differential cell
counts with Giemsa-stained blood smears
showed an increasing ratio ofmononuclear
cells to PMN with time after BCG
infection.
Effect of pentoxifylline on metastasis
First the platelet count was made after
i.v. injection of 2 x 105 tumour cells into
normal mice. The platelet count decreased
to 60% of controls at 30 min and 42% at
3 h after tumour inoculation. The methyl-
xanthine derivative, pentoxifylline (Tren-
tal, Hoechst, Germany), is shown to
improve the deformability of red blood
cells and decrease blood viscosity. (Muller
et al., 1975; Ehrly, 1976). Furthermore,
Gastpar (1974) noted that it inhibited
platelet adhesion and aggregation to
circulating sticky tumour cells, and their
attachment to the endothelium, and
blocked subsequent thrombus formation.
The next experiment was performed to
TABLE VIII.-Haematological changes inBCG-infected mice.*
BCG RBC WBC Platelets
Group treatment (104/mm3) (per mm3) (104/mm3)
1 886+55 6070+ 1390 41-5+ 7-7
2 4 wks before 1030 ± 39t 5748+ 1810 45 0+ 9-5
3 8 wks before 1020 85$ 5610+ 2270 48-6 + 13-6
4 12wksbefore 976+137 7360+2040 53-2 10 1§
* Each value represents the mean of 5 + s.d.
t P < 0 001 in comparison with Group 1.
$ P < 0 01 in comparison with Group 1.
§ P < 0-05 in comparison with Group 1.
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determine whether pentoxifylline de-
creased distant metastasis in our system.
One mg of BCG was inoculated into one
hind foot pad 7 weeks before tumour chal-
lenge. BCG-infected mice were divided
into 3 groups. Group 1 served as controls
without any further treatment. Group 2
and 3 received i.v. 10 mg/kg and 20 mg/kg
of pentoxifylline respectively, 30 min
before tumour challenge. All mice were
injected with 3 x 105 tumour cells into the
BCG-primed site. As shown in Table IX,
TABLE IX.-Effect of pentoxifylline on
metastasis in mice inoculated with tumour
at the BCG-primed site*
Group
l
2
3
Pentoxi-
fyllinet
(mg/kg)
No. of mice with
metastases 21 days
after tumour
challenge
Popliteal
lymph
node Lung
5/8 4/8
10 0/8T 2/8
20 0/8t 1/8
* 3 x 105 tumour cells.
t Dissolved in saline and 0-1 ml injected i.v. 30
min before tumour challenge.
$ 0-02 <P <0-05 in comparison with Group 1.
no metastasis was found in the regional
lymph node in mice receiving both doses
of pentoxifylline. The rate of pulmonary
metastasis was also diminished by ad-
ministration of pentoxifylline. Since there
was no change in the RBC count and a
slight decrease in platelet level 60 min
after injection ofpentoxifylline (20 mg/kg)
in normal mice (data not shown) it seemed
likely that such reduction of distant
metastasis should be due to pentoxifylline
inhibiting platelet adhesiveness and aggre-
gation.
DISCUSSION
It was previously reported that immu-
nopotentiation with BCG was achieved
when BCG and antigen were injected into
the same site (Miller et al., 1973; Ishibashi
et at., 1977a). Furthermore, several investi-
gatorsreported that directcontactbetween
BCG and tumour cells was necessary to
inhibit tumour growth (Bartlett et al.,
1972; Baldwin & Pimm, 1973). We
therefore supposed that suppression of
tumour growth would be obtained when
tumour cells were inoculated into the
BCG-primed site. However, we found that
distant metastases in the lungs and the
draining lymph node occurred unexpect-
edly, when a high tumour dose was in-
jected into the BCG-primed site, whereas
a low dose of tumour cells did not grow
(Ishibashi et al., 1978a). The mechanisms
of the promotion of distant metastasis
in our experimental system could be
classified as local or systemic (specific or
nonspecific). We thought that the in-
creased egress of tumour cells from the
BCG-primed site would be important as a
local factor, since Fidler (1973a) reported
that the number of lung metastases was
proportional to the number of viable cells
injected i.v. Moreover, Courtade et al.
(1975) noted that capillary density in-
creased in BCG lesions in rabbits. Our
previous studies revealed that direct
plaque-forming cells were produced in
distant lymphoid organs when SRBC were
injected into the BCG-primed site (Ishi-
bashi et al., 1978b). These results sug-
gested that a majority of foreign bodies
such as SRBC or tumour cells injected into
the BCG site easily migrate out through
lymphatics and blood vessels as a result
of the inflammatory changes induced by
BCG. The present experiments revealed
that 125I-labelled SRBC and/or tumour
cells injected into the BCG-primed site
rapidly egressed from the injection site.
The egress of tumour cells from the BCG-
primed site was significantly greater than
that seen in normal mice. These results
couldexplain, at least inpart, the develop-
ment of distant metastases in BCG-
pretreated mice. Moreover the uptake of
1251-labelled SRBC and/or tumour cells in
lungs and the draining lymph node occur-
red within 3 h of injection. These findings
are consistent with the results showing
early development of distant metastases,
as presented in Table II. As shown in
Table V, in the case of tumour injection
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into the contralateral foot pad in BCG-
pretreated mice, the incidence and the
number of metastases in the lungs was
less than when the tumour was injected
into the BCG-primed site. It seemed that
both the increased release of tumour cells
from the site of injection, and some
systemic effect of BCG infection, were
important for the development of distant
metastasis, which did not occur in normal
mice. When tumour cells were injected
i.v. at a distance from the BCG-primed
site, there was a significant inhibition of
pulmonary metastasis following a low
dose of tumour inoculum. These data are
consistent with the previous results show-
ing a slight inhibition of tumour growth
after inoculation of a low tumour dose
in the contralateral foot pad (Ishibashi
et al., 1978a). However, it was of interest
that, in the case of a high tumour dose,
there was slight promotion of pulmonary
metastasis in BCG-pretreated mice. These
results suggested that the inhibitory effect
of BCG pretreatment on tumour growth,
whether specific or nonspecific, could not
operate when the dose oftumour inoculum
exceeded some threshold. On the contrary,
some systemic nonspecific effect of BCG
infection might even promote tumour
growth in such a case. We observed, how-
ever, that even in normal mice radio-
labelled tumour cells injected into the foot
pad egressed and entered distant organs.
These results agreed with the report by
Fisher & Fisher (1967) that s.c. inoculation
of Walker tumour cells into the legs was
followed by a rapid egress ofcells from the
injection site to other organs. Neverthe-
less, in our system distant metastases were
never seen in normal mice. We consider
that the systemic effect of BCG infection
on specific tumour immunity might pro-
mote distant metastasis. It was supposed
that BCG might alter the host's immune
response to a tumour by the production of
blocking factors, since we previously
observed that BCG initially stimulated
cell-mediated immunity, but later en-
hanced antibody formation (Ishibashi
et al., 1977a, b). The results in Table VII
show that strong tumour immunity de-
veloped in the BCG-pretreated mice with
orwithout excision ofthe primary tumour,
whereas distant metastasis occurred simi-
larly in both groups of BCG-pretreated
mice. It was therefore concluded that
tumour cells were arrested in the distant
organs such as lungs immediately after
tumour challenge and grew to metastases
before tumour immunity developed or
while it was yet weak, since several
investigators noted that a weak incipient
immune response stimulated rather than
inhibited tumour growth (Prehn, 1972;
Fidler, 1974). In general, the development
of tumour metastasis was thought to be
influenced by many factors, such as
tumour-cell properties (Fidler, 1973b;
Nicolson&Winkelhake, 1975) hostimmune
response (Baldwin & Pimm, 1973; Fidler,
1974) platelet level (Gasic etal., 1968, 1973)
fibrin formation (Wood, 1958) endothelial
injury in the capillary bed (Fidler &
Zeidman, 1972) and tumour immuno-
geinicity (Fidler et al., 1979) etc. Subse-
quently we considered that some systemic
nonspecific effect of BCG might promote
distant metastasis. It is assumed that
more tumour cells are trapped due to the
change in capillary bed produced by
BCG-granuloma, because BCG infection
sometimes causes granuloma production
in the lungs. But histological examination
revealed no granuloma around the meta-
static foci in the lungs. Gordon et al.
(1977) noted that BCG administered to
irradiated mice increased the numbers of
haemopoietic precursor cells in the marrow
and spleen. It seems likely from their
findings that BCG might increase the
production of megakaryocytes and the
platelet level might then increase in BCG-
pretreated mice which would facilitate
pulmonary metastasis. The results in
Table VIII showed that BCG infection
induced a significant increase in platelet
count. Gasic et al. (1973) noted that many
tumours produced thrombocytopenia in
vivo, which was most active against meta-
stases produced by tumours with the capa-
city to aggregate platelets. The tumour
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used in the present experiments also pro-
duced thrombocytopenia. Therefore, the
reduction of distant metastases by pen-
toxifylline implied peripheral-blood chan-
ges such as the increased platelet count
in BCG-infected mice, which induced
distant metastasis and inhibited the
expression of specific tumour immunity.
The authors would like to thank Dr Kenzo
Tanaka, Professor of 1st Department of Pathology,
Faculty of Medicine, Kyushu University, for helpful
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